Introduction
We have proposed that inflammation, hormones, such as insulin, estrogen and androgen, and energy-related factors converge into a central pathway, convergence of hormones inflammation & energyrelated factors (CHIEF), which ultimately influences colorectal cancer risk (1) . This hypothesized pathway is based on epidemiological data that suggest the importance of these key elements in colon and rectal cancer etiology (2) (3) (4) (5) (6) (7) (8) . Major components of this pathway relate to metabolic signaling, insulin sensitivity and cellular energy balance and their interface with energy-and inflammation-related factors.
There are two major arms of the pathway that regulate insulin sensitivity and ultimately link it to other components of the pathway. One arm contains a serine/threonine protein kinase 11 (STK11) or LKB1 and is involved in the regulation of mammalian target of rapamycin (mTOR). A different portion of the pathway that responds to insulin, estrogen and androgen and certain proto-oncogene growth factors contains PTEN (phosphatase tensin homolog deleted on chromosome 10). Components of the pathway are tumor suppressors have been associated with epigenetic inactivation in breast cancer (9) and poor prognosis and survival after cancer diagnosis (10) . The importance of this pathway for colon and rectal cancers is largely unknown.
STK11 or LKB1, a tumor suppressor gene, responds to changes in cellular energy balance [adenosine triphosphate (ATP) levels] (11, 12) and governs whole body insulin sensitivity (13, 14) . In cells with excess adenosine monophosphate due to altered energy homeostasis, serine threonine protein kinase (STK11) phosphorylates the adenosine monophosphate-dependent kinase (PRKAA1 and PRKAG2) (11, (15) (16) (17) , which in turn phosphorylates proximal substrates like tuberous sclerosis complexes (TSCs) 1 and 2. TSC1 and TSC2 have been shown to be involved in the regulation and proliferation of cell size and may have other roles given their location in an insulin signaling pathway. FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1 alias mTOR) ultimately represses anabolic processes (ATP utilization) and enhances catabolic processes (ATP generation), restoring the system toward normal energy homeostasis. mTOR is implicated further in tumorigenesis by the fact that rapamycin inhibits tumor growth (18) .
Like STK11, PTEN has a dual role as a tumor suppressor and regulator of metabolic signaling and has been identified as a negative regulator of cell growth in the insulin/insulin-like growth factor signaling pathways. Loss of functioning from germ line mutations in the PTEN gene cause PTEN hamartoma tumor syndrome (19) . PTEN acts as a metabolic regulator by modulating signaling via the phosphatidylinositol 3-kinase (PI3K) and the v-akt murine thymoma viral oncogene homolog 1 (Akt1 also known as protein kinase B) pathway, downstream of the insulin receptor. Akt1-dependent phosphorylation negatively regulates the functioning of TSC1 and TSC2 and links to inflammation via nuclear factor-kappaB (20) .
The elements along the conserved pathway that are being examined in this report are highlighted in Figure 1 . While this pathway for the most part has not been investigated in epidemiologic studies of cancer, genetic variation in this pathway in conjunction with environmental factors may help us understand cancer incidence and outcome. Thus, we evaluate genetic variation in this signaling pathway to determine risk associated with colon and rectal cancer, the specific tumor markers and epigenetic changes that are unique to this pathway and its possible impact on survival.
Methods
Data for the study come from two case-control studies conducted in Utah, the Northern California Kaiser Permanente Medical Care Program (KPMCP) and the Twin Cities Metropolitan area of Minnesota (colon cancer study only). Eligibility criteria included being between 30 and 79 years of age at time of diagnosis, English speaking, mentally competent to complete the interview, no previous history of colorectal cancer and no known (as indicated on the pathology report or by self-report) familial adenomatous polyposis, ulcerative colitis or Crohn's disease. Controls were frequency matched to cases by sex and five years age groups. Controls were randomly selected from membership lists (KPMCP) or from driver's license list (Minnesota). In Utah, controls !65 were randomly selected from lists provided by the Centers for Medicare and Medicaid Services and controls ,65 were randomly selected from driver's license lists. Study eligibility and recruitment details of the study have been published previously (4, 5) . Cooperation rates were 83% at KPMCP, 76% at Utah and 67% Minnesota (colon cases); 73% at KPMCP, 53% at Minnesota and 69% at Utah (colon controls); 75.4% at KPCMP and 69.7% at Utah (rectal cases) and 69.9% at KPMCP and 67.2% at Utah (rectal controls).
The current analysis is restricted to subjects who provided a blood sample. The colon cancer study population consists of non-Hispanic white cases (n 5 1444) and controls (n 5 1841), Hispanic or American Indian cases (n 5 60) and controls (n 5 75) and African-American cases (n 5 70) and controls (n 5 54) the rectal cancer study population consists of non-Hispanic white cases (n 5 657) and controls (n 5 856), Hispanic or American Indian cases (n 5 63) and controls (n 5 69), African-American cases (n 5 31) and controls (n 5 44) and Asian cases (n 5 40) and controls (n 5 30).
Trained and certified interviewers collected diet and lifestyle data as described previously (21, 22) using the same data questionnaire and study procedures for both the colon and rectal studies. The referent year for the study was the calendar year $2 years prior to date of diagnosis (cases) or selection (controls). Information was collected on demographic factors, such as age, sex and study center, and on exposures including diet, physical activity, aspirin and non-steroidal drug use, body size and other lifestyle factors including medical, family and reproductive history.
DNA was extracted from blood drawn from study participants. A customized Illumina bead array platform was developed based on candidate genes. Since there were no known functional single-nucleotide polymorphisms (SNPs) in the genes of interest, tagging SNPs were selected. Tagging SNPs were chosen by application of an algorithm based on the methods of Carlson et al. (23) , using the following parameters: an r 2 5 0.9 defined linkage disequilibrium (LD) blocks using a Caucasian LD map, minor allele frequency .0.1, range 5 À1500 bp from the initiation codon to þ1500 bps from the termination codon and two SNPs/LD bin where possible.
As a control for quality, 4.4% of samples were duplicated in all genotyping. The sample success rates was 97.6%, the genotype call rate was 99.9%; there was 100% reproducibility as measured by genotypes among duplicate sample pairs. Individual tagSNPs were assessed to determine if they were in HardyWeinberg equilibrium after controlling for the false discovery rate (FDR) (24) in non-Hispanic white controls. Supplementary material is available at Carcinogenesis Online and has a complete listing of all tagSNPs assessed along with the minor allele frequency and location.
Tumor registry data were obtained to determine disease stage at diagnosis and months of survival after diagnosis. Disease stage was categorized by Surveillance, Epidemiology and End Results staging of local, regional and distant disease as well as by the American Joint Committee on Cancer staging criteria. Local tumor registries provided information on patient follow-up, including vital status, cause of death and contributing cause of death. Survival months were calculated based on month and year of diagnosis and month and year of death or last contact for those individuals who were still alive.
We have previously evaluated tumors for CpG island methylator phenotype (CIMP), microsatellite instability (MSI), TP53 mutations and KRAS2 mutations (25) (26) (27) (28) and were therefore able to evaluate tagSNPs with specific tumor markers. Details for methods used to evaluate these epigenetic and genetic changes in tumors have been described in previous publications (25) (26) (27) (28) .
Statistical analysis
Statistical analysis involved several steps and focused on testing the following hypotheses: tagSNPs within the candidate genes are associated with colon and rectal cancer; tagSNPs within candidate genes act jointly to alter risk of colon and rectal cancer and tagSNPs are associated with specific tumor markers. Initial weeding of tagSNPs was done by dropping one of the two tagSNPs if the r 2 between the two was !0.8, preferentially selecting the SNP with the lower proportion missing (supplementary material, available at Carcinogenesis Online, shows the LD between all tagSNPs within a gene). SAS 9.2 (Cary, NC) was used to perform all of the statistical analyses except when use of hapConstructor is noted. Figure 2 shows a detailed analysis plan to identify important tagSNPs and determine associations. To identify tagSNPs within each candidate gene associated with colon cancer, rectal cancer and specific tumor markers, a stepwise logistic regression analysis was run for each of these outcomes. tagSNPs from these analysis were shown to represent the best predictors of outcomes of interest. We calculated minimally adjusted odds ratios for tagSNPs adjusting for age at diagnosis or selection, race, sex and study site using the MAX test to assess whether there was any relationship (recessive, unrestricted or dominant) between colon or rectal cancer and each of the individual tagSNPs (29) . Additionally, haplotypes were constructed for those tagSNPs within genes that remained significant in the stepwise logistic regression models. Risk estimates for haplotypes were calculated using the weighed option comparing the specific haplotype to all other haplotypes. Those with missing data were excluded from the haplotype analysis. Adjustment of body mass index, cigarette smoking, dietary energy, fiber and calcium, long-term vigorous physical activity, regular use of aspirin/nonsteroidal anti-inflammatory drugs within the past 2 years and family history of colorectal cancer in first-degree relatives did not appreciably alter the risk estimates, therefore data are presented for the minimally adjusted model.
We used hapConstructor (a module of Genie 2.6.2 software; http: //www-genepi.med.utah.edu/Genie/index.html) as a tool to evaluate combinations of SNPs across selected genes. A user-specified significance threshold of 0.01 was selected at two-locus step and P of 0.001 at the three-locus step to take into account the number of comparisons being made for the nine genes. This level of stringency for significance in hapConstructor has been used previously in similar types of analyses (30) . The multi-locus genotype results from hapConstructor Genetic variation in a metabolic signaling pathway were then assessed using stepwise multiplicative interaction logistic regression models. We evaluated interaction between tagSNPs using a goodness of fit test that compared the maximum likelihood ratios of a model with and without an interaction term using Chi-squared test with 1 d.f.. HapConstructor also was used to calculate the FDR using a permutation test for each gene to determine the likelihood that the findings would be replicated in 1000 permutations of the data. An adjusted P value for main effects was determined using the method by Conneely and Boehnke (31) .
Tumor markers, including CIMPþ, KRAS2 and TP53 were evaluated with individual tagSNPs using a multinomial generalized estimating equations approach due to the associations between tumor markers, adjusting for age, sex, race and study site (32, 33) . P for trend was calculated using the likelihood ratios test statistic with 1 d.f. from a separate unconditional logistic model for each tumor mutation. MSI was evaluated for colon tumors but not for rectal tumors as MSI is too rare to evaluate precisely in the sample size available (34) .
Results
The study population included 871 male and 685 female colon cancer cases and 1047 male and 909 female age-and sex-matched controls with complete study data. There were 451 male and 303 female rectal cancer cases and 541 and 418 corresponding controls. The average age of colon cancer participants was 65.0 and of rectal cancer participants was 61.8. Eight of the nine genes assessed had one or more SNP associated with either colon or rectal cancer (Table I) .
Four of the nine genes showed independent associations with colon cancer (Table II) . Both FRAP1 rs2024627 and rs1057079 were associated with colon cancer (pairwise r 2 5 0.71 and D# 5 0.85); we present findings for rs1057079 since it remained significant in a stepwise regression analysis and the adjusted P value was significant at the 0.01 level. The TT genotype of TSC2 rs3087631 was inversely associated with colon cancer. PRKAA1 showed a significant doseresponse inverse association with the C allele. Six polymorphisms of PRKAG2 were associated with colon cancer, although most associations were modest, ranging from 0.73 for rs6464170 to 1.51 for rs9648723. Generally, a recessive model provided the best fit. For colon cancer, significant tagSNP by tagSNP interactions were observed between both FRAP1 rs2024627 and rs1057079 and PRKAG2 rs1029947 and rs1104897. Additionally, PRKAG2 rs7801616 interacted significantly with PRKAA1 rs461404 (P 5 0.03). Haplotype analysis did not show any meaningful associations beyond those observed for individual tagSNPs (supplementary material is available at Carcinogenesis Online).
Five of the nine genes evaluated were associated with risk of developing rectal cancer (Table II) . In many instances, the recessive model of inheritance provided the best fit. The rs13295634 tagSNP of TSC1 was associated with a significant 40% reduction in the odds of rectal cancer. Associations with PTEN, although significant were more modest. STK11 rs741765 was associated with a 48% increased odds of rectal cancer for those with the AA genotype. The strongest associations were observed for rs1104897 of the PRKAG2 gene where we observed an 88% increased odds for the AA genotype; there was a significant linear trend from the GG wild-type to the AA rare genotype (P linear trend ,0.01). The PRKAG2 rs880915 and rs4726096 tagSNPs interacted significantly with TSC1 rs2809243 and rs11243929 (P interaction 0.002 and 0.01). Haplotype analysis did not show any meaningful associations beyond those observed for individual tagSNPs.
Further assessment of polymorphisms within the candidate genes and specific tumor markers revealed associations for unique pathways beyond those observed for colon and rectal cancer overall (Tables III  and IV) . FRAP1, PRKAA1 and TSC1 were associated with CIMPþ and MSIþ colon tumors (Table III) . PRKAG2 rs7789674 was associated with TP53 mutated and MSIþ colon tumors, whereas PRKAG2 rs2536082 was associated with KRAS2 mutations. PIK3Ca rs7651265 AG/GG genotypes were associated with a 50% increased odds of KRAS2 rectal tumors (Table IV) . PRKAG2 rs6964824 was associated with an $40% reduced odds of both KRAS2 and TP53 rectal tumors, whereas PRKAG2 rs4128396 and rs4725431 was statistically significantly associated with altering risk of CIMPþ rectal tumors.
Discussion
Several genes involved in metabolic and insulin signaling were associated with both colon and rectal cancer, although different genes and tagSNPs were often associated with the two cancer sites. Some of the strongest associations were for CIMPþ and MSIþ colon tumors, suggesting a unique role for this pathway.
FRAP1, also known as mammalian target of rapamycin or mTOR, is central to metabolic signaling, being activated by insulin, insulinlike growth factors and other growth factors when nutrients are plentiful and being inactivated during cellular starvation (35) . TSC1 and TSC2 link upstream growth factor signaling to mTOR and negatively regulates cell expression and b-catenin signaling activity (36) . TSC2, also known as tuberin, specifically has been shown to be involved in insulin signaling, tumor suppressor functions and regulation of cell growth. In our data, we observed that tagSNPs in both FRAP1 and TSC2 genes altered risk of colon cancer.
Adenosine monophosphate-activated protein kinase (AMPK) plays a central role in regulating cellular energy status (37) . The official gene name for AMPK is PRKA. AMPKs consist of an a subunit (gene subunits A1 and A2) and regulatory subunits b (gene subunits B1 and B2) and c (gene subunit G1, G2 and G3). We observed associations with colon cancer for the A1 and G2 subunits. The c2 subunit has been associated with both glucose and lipid metabolism (38) . In our data, both PRKAA1 and PRKAG2 tagSNPs were associated with colon cancer. Furthermore, they significantly interacted with each other to alter colon cancer risk. In our data, the PRKAG2 tagSNPs also were associated with rectal cancer; of interest was the observation that different tagSNPs were responsible for the associations. TagSNPs for the other A and B subunits were assessed with null associations (data not shown in tables).
Other aspects of the proposed pathway appeared to be important for rectal cancer. STK11 (alias LKB1) is a tumor suppressor that is inactivated in Peutz-Jeghers syndromes and in some sporadic lung adenocarcinomas (39) . It has been shown to directly activate AMPK and regulate apoptosis in response to energy stress (17) and to repress mTOR under low ATP conditions (39) . We observed a statistically significant association between tagSNPs of the STK11 gene and risk of rectal cancer.
PI3K gene official name PIK3CA is an early event in cells responding to growth factors, cytokines and hormones including insulin (40) . PI3K induces the activation of Akt1 (alias protein kinase B). PTEN, a tumor suppressor gene, can inactivate this pathway and has been associated with multiple cancers and alterations in cell cycle regulation and apoptosis (41) . This PI3K-Akt pathway is recognized as an important regulator of cell proliferation and survival and is thought to be involved in mediating the effects of mTOR (42) . It has been shown that inflammation-related factors can activate mTOR and promote tumor angiogenesis by phosphorylating TSC1 (also known as hamartin) and thereby inactivate the TSC1-TSC2 complex (43, 44) . Statistically significant associations were seen between genetic variation in PI3KCA, PTEN and TSC1 and risk of developing rectal cancer.
Evaluation of tumor markers has given some insight into how this pathway works in the development of colon and rectal cancer. Of interest is the somewhat consistent associations observed for CIMPþ colon tumors and MSIþ tumors. While most associations were for FDR HWE, false discovery rate Hardy-Weinberg equilibrium probability.
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what could be classified as CIMP/MSIþ tumors, there is suggestion for CIMP2 tumors that are characterized by CIMPþ and KRAS2-mutated tumors. We detected significant associations between CIMPþ rectal tumors and PRKAG2. There were too few MSIþ rectal tumors to evaluate. However, for rectal cancer, we observed unique non-CIMPþ associations for both PRKAG2 (rs6964824) and PIK3CA (rs7651265) where associations were strongest for KRAS2 and TP53 mutated tumors. It is noteworthy that both PTEN and STK11/LKB1 are considered haploinsufficient tumor suppressors-loss of function of one allele results in an abnormal phenotype. Thus, PTEN and STK11 both deviate from classic genetic models, which stipulate that biallelic inactivation of tumor suppressors is necessary for tumorigenesis (45) Moreover, recent laboratory studies have identified novel mechanisms by which inflammatory mediators derived from the cyclooxygenase and lipoxygenase pathways can directly inactivate both STK11 (46) and PTEN (47) . Disruption of tumor suppressors by inflammatory mediators seems especially relevant to cancers associated with chronic inflammation or overexpression of cyclooxygenase and lipooxygenase, such as colorectal cancer. In this context, interference with PTEN's and STK11's physiological antagonism signals from growth factors, insulin and oncogenes may confer risk for neoplastic diseases that are modulated in distinctive ways by genetic variability among genes dispersed in the CHIEF pathway. The pathway and selection of the genes for analysis were based on biological mechanisms described above and their potential importance to colon and rectal cancer given epidemiological data that suggest that energy homeostasis and inflammation are important (5, 48) .
In this study, we examined genetic variation in nine important genes along our proposed CHIEF pathway (1). While we hypothesized that the genes would be important in influencing risk associated with colon and rectal cancer, given limited information on these genes, we did not hypothesize any given tagSNP would be most important. Thus, a limitation of the study is the degree of exploration necessary to Genetic variation in a metabolic signaling pathway obtain a better understanding for the importance of this pathway in colon and rectal cancer. We report the findings that we believe are important and invite others to explore these in available datasets. However, since many comparisons were made to test our study hypotheses, we cannot rule out that an observed result may have occurred by chance, and only FRAP1 remained statistically significant after adjustment for multiple comparisons. However, all methods of multiple comparisons are very conservative when exploring candidate genes with 'a prior' hypothesis. tagSNPs within a gene are not truly independent observations. Additionally, we present odds ratio as an estimate of association and do not report P values per se. Our FDR assessment generally showed that a P value for the MAX test was comparable with a FDR q value of 0.10-0.15 or that 10-15% of the time the findings could be false positive. A strength of the study is the depth of data available so that we could adjust for possible confounding variables such as body mass index, physical activity, diet and nonsteroidal anti-inflammatory drug use. The extensive tumor data allowed us to explore the biological implications of the pathway. Genetic variation in this metabolic signaling pathway was associated with both development of colon and rectal cancer. Our data further suggest that this pathway may influence risk through epigenetic changes. Although replication of our results by other studies is needed, we believe that the data presented adds to our understanding of the biological basis of colon and rectal cancers.
Supplementary material
Supplementary materials can be found at http://carcin.oxfordjournals .org/ Funding National Cancer Institute (CA48998, CA61757); Utah Cancer Registry, which is funded by Contract #N01-PC-67000 from the National Cancer Institute, with additional support from the State of Utah Department of Health, the Northern California Cancer Registry and the Sacramento Tumor Registry.
